Physician profile
Erin Mclaughlin
NPI 1174244735
$3,479.28
in general payments reported to CMS, 2019-2025
44 companies · $1,561 in 2025
The $1,561 reported for 2025 was more than what 88% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $1,639 · 2024: $280 · 2025: $1,561.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,500 · Travel and Lodging: $851 · Education: $128.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,500.13 |
| Travel and Lodging | $851.17 |
| Education | $127.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pacira Pharmaceuticals Incorporated | $1,029.37 | 2023 | Iovera, Zilretta, Exparel |
| Amgen INC. | $264.05 | 2023-2025 | Evenity, Prolia, Prolia |
| Convatec INC. | $251.95 | 2023 | |
| Janssen Biotech, INC. | $207.74 | 2025 | Rybrevant, Carvykti, Talvey |
| Incyte Corporation | $206.46 | 2025 | Jakafi, Zynyz, Monjuvi |
| Cerapedics INC. | $119.36 | 2023-2024 | I-Factor Peptide Enhanced Bone Graft |
| Merck Sharp & Dohme LLC | $110.44 | 2025 | Keytruda, Reblozyl, Keytruda Qlex |
| Vertex Pharmaceuticals Incorporated | $78.38 | 2024-2025 | |
| Genentech USA, INC. | $75.56 | 2025 | Itovebi, Venclexta, Polivy |
| Glaxosmithkline, LLC. | $68.11 | 2025 | Jemperli, Zejula, Blenrep |
| Bayer Healthcare Pharmaceuticals INC. | $66.48 | 2025 | |
| Beone Medicines USA, INC. | $61.93 | 2025 | Brukinsa, Tevimbra |
| Astellas Pharma US INC | $60.99 | 2025 | Vyloy |
| Bioventus LLC | $58.27 | 2023 | Bonescalpel, Exogen Ultrasound Bone Healing System |
| Regeneron Healthcare Solutions, INC. | $57.01 | 2025 | Libtayo |
Show all 44 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $52.16 | 2025 | Tagrisso |
| Abbvie INC. | $49.99 | 2025 | |
| Novocure INC. | $44.51 | 2025 | Optune Lua (Novottf-200t) |
| Puma Biotechnology, INC. | $43.66 | 2025 | |
| Medtronic, INC. | $40.69 | 2023-2024 | Intellis Adaptivestim |
| Lilly USA, LLC | $36.58 | 2025 | Verzenio, Jaypirca, Retevmo |
| Si-Bone, INC. | $27.54 | 2024 | |
| Rigel Pharmaceuticals, INC. | $27.13 | 2025 | Rezlidhia, Gavreto, Tavalisse |
| Caris Mpi, INC. | $25.73 | 2025 | Mi Cancer Seek |
| Deciphera Pharmaceuticals INC. | $25.42 | 2025 | Qinlock, Romvimza |
| Daiichi Sankyo INC. | $24.63 | 2025 | Datroway |
| Celgene Corporation | $23.45 | 2025 | Reblozyl |
| Depuy Synthes Sales INC. | $23.26 | 2023 | Vivigen Mis Delivery System |
| Fidia Pharma USA INC. | $22.45 | 2025 | Hymovis, Triluron |
| Smoky Mountain Surgical LLC | $22.28 | 2024 | |
| Djo, LLC | $21.98 | 2023 | Cmf |
| Takeda Pharmaceuticals U.S.A., INC. | $21.83 | 2025 | Vpriv |
| Aveo Pharmaceuticals, INC. | $21.83 | 2025 | |
| Iovance Biotherapeutics, INC. | $20.88 | 2025 | Amtagvi |
| Pharmaessentia USA Corporation | $20.83 | 2025 | Besremi |
| Nevro Corp. | $20.45 | 2024 | Senza |
| Organogenesis INC. | $20.44 | 2025 | Affinity |
| Emd Serono, INC. | $19.90 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $19.67 | 2025 | Opdivo |
| Pharmacosmos Therapeutics INC. | $19.10 | 2025 | Monoferric |
| Sanara Medtech INC. | $17.27 | 2023 | Celleraterx |
| Arteriocyte Medical Systems, INC. | $17.02 | 2023 | Magellan |
| Geron Corporation | $16.76 | 2025 | Rytelo |
| Breg, INC | $15.74 | 2023 | Breg Vpulse, Plasmaflow, Polarcarewave |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Erin Mclaughlin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.